LLY
LLY
NYSE · Pharmaceuticals

Eli Lilly and Co.

S&P 500 Mega-Cap Stocks Blue Chip Stocks Pharmaceutical Stocks Healthcare Stocks Best Dividend Stocks
$1,058.56
+49.04 (+4.86%)
As of Feb 24, 1:03 PM ET ·
Financial Highlights (FY 2026)
Revenue
67.82B
Net Income
21.48B
Gross Margin
83.0%
Profit Margin
31.7%
Rev Growth
+31.7%
D/E Ratio
2.37
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 83.0% 83.0% 56.4% 56.4%
Operating Margin 40.3% 36.3% 27.5% 24.1%
Profit Margin 31.7% 30.1% 18.8% 23.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 67.82B 51.50B 262.19B 288.72B
Gross Profit 56.32B 42.77B 147.80B 162.76B
Operating Income 27.37B 18.70B 72.23B 69.71B
Net Income 21.48B 14.68B 49.23B 68.90B
Gross Margin 83.0% 83.0% 56.4% 56.4%
Operating Margin 40.3% 36.3% 27.5% 24.1%
Profit Margin 31.7% 30.1% 18.8% 23.9%
Rev Growth +31.7% +31.7% +3.8% -0.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 336.72B 336.72B 59.02B 45.19B
Total Equity 142.04B 142.04B 657.24B 666.99B
D/E Ratio 2.37 2.37 0.09 0.07
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 27.44B 19.80B 80.48B 106.53B
Free Cash Flow — — 35.91B 45.81B